| Thread / Poster |
 |
Author |
|
Replies |
|
Last reply |
|
| A case of inhibitor to factor IX in a two years old boy with severe congenital hemophilia B. |
|
skhiri rania |
|
1 |
|
6/25/2012 11:27:00 PM
|
|
|
| USE OF HIGH DOSES FVIII/ VON WILLEBRAND FACTOR CONCENTRATE IN A PATIENT WITHTYPE III VON WILLEBRAND DISEASE AND HIGH LEVEL INHIBITOR |
|
M Nieves Alonso Escobar |
|
1 |
|
6/25/2012 5:30:00 PM
|
|
|
| Efficacy of a Recombinant Factor IX in Mouse Models of Hemophilia B |
|
Werner Hllriegl |
|
1 |
|
6/25/2012 4:33:00 PM
|
|
|
| Efficacy of a New Recombinant Factor VIIa in Animal Models of Hemophilia |
|
Alexandra Schiviz |
|
1 |
|
6/25/2012 4:16:00 PM
|
|
|
| Efficacy of a PEGylated Variant of Recombinant Factor VIII in Mouse Models ofHemophilia A |
|
Werner Hllriegl |
|
1 |
|
6/25/2012 4:15:00 PM
|
|
|
| In vitro Characterisation of FACTOR X in Global Haemostasis Tests |
|
Joanne Lloyd |
|
1 |
|
6/25/2012 3:23:00 PM
|
|
|
| In vitro reversal of the direct Xa inhibitor Rivaroxaban using High Purityfactor X concentrate (FACTOR X) |
|
Joanne Lloyd |
|
1 |
|
6/25/2012 3:18:00 PM
|
|
|
| Contribution of chromatography to virus and TSE removal in the FactorVIII/VWFOptivate process |
|
Peter Feldman |
|
1 |
|
6/25/2012 2:58:00 PM
|
|
|
| Analysis of the Composition of a Factor VIII Concentrate, Optivate |
|
Sarah Kingsland |
|
1 |
|
6/25/2012 2:53:00 PM
|
|
|
| Safety of BAX 855, a polyethylene glycol (PEG) conjugated full-lengthrecombinant Factor VIII product |
|
Eva Muchitsch |
|
1 |
|
6/25/2012 10:26:00 AM
|
|
|
| Absorption, Metabolism, Distribution, and Excretion of a PEGylated Variant ofRecombinant Factor FVIII Following Intravenous Administration to Rats |
|
Reinhard Stidl |
|
1 |
|
6/25/2012 10:20:00 AM
|
|
|
| Safety of a PEGylated variant of recombinant factor VIII after repeated application in rats and macaques |
|
Margit Spatzenegger |
|
1 |
|
6/25/2012 10:17:00 AM
|
|
|
| Collaborative Study for the Establishment of Korean Standard for Blood Products(Factor IX Concentrate) |
|
JiSuk Seo |
|
1 |
|
6/25/2012 6:53:00 AM
|
|
|
| Pharmacokinetics (PK) of recombinant and plasma-derived factor VIII (FVIII) products in pediatric patients with severe hemophilia A |
|
Melanie Steele |
|
1 |
|
6/25/2012 5:31:00 AM
|
|
|
| CRYOPRECIPITATE TRANSFUSION IN ON-PUMP CARDIAC SURGERY |
|
Katerina Pavenski |
|
1 |
|
6/25/2012 4:17:00 AM
|
|
|
| Variable Activation Kinetics of Different Recombinant Full Length and B-DomainDeleted Factor VIII Concentrates |
|
Saskia Pahl |
|
1 |
|
6/22/2012 2:45:00 PM
|
|
|
| Assessment of preclinical safety for BAX 326, Baxters recombinant human factorIX |
|
Barbara Dietrich |
|
1 |
|
6/22/2012 1:48:00 PM
|
|
|
| Preclinical Safety of a new Recombinant Factor VIIa |
|
Barbara Dietrich |
|
1 |
|
6/22/2012 1:44:00 PM
|
|
|
| Repeated Application of a new Recombinant Factor IX in Rats and Macaques |
|
Barbara Dietrich |
|
1 |
|
6/22/2012 1:41:00 PM
|
|
|
| Characterization of the binding properties of recombinant FVIII concentrateswith von Willebrand Factor |
|
Daniele Pillitteri |
|
1 |
|
6/22/2012 11:44:00 AM
|
|
|
| EXPERIENCE IN THE TREATMENT OF CUBAN PATIENTS WITH SEVERE BLEEDING USINGRECOMBINANT FVIIA |
|
Dunia de la Caridad Castillo González |
|
1 |
|
6/21/2012 8:53:00 PM
|
|
|
| Characterization of BAX 326 a recombinant human factor IX drug candidate |
|
Peter Turecek |
|
1 |
|
6/21/2012 6:50:00 PM
|
|
|
| Characterization of BAX 817 a recombinant FVIIa drug candidate |
|
Peter Turecek |
|
1 |
|
6/21/2012 6:45:00 PM
|
|
|
| Structural characterization of BAX 855, a PEGylated recombinant FVIII |
|
Peter Turecek |
|
1 |
|
6/21/2012 6:41:00 PM
|
|
|
| Functional characterization of BAX 855, a PEGylated recombinant FVIII |
|
Peter Turecek |
|
1 |
|
6/21/2012 6:35:00 PM
|
|
|
| Development of a large scale production process for BAX 855, a PEGylated rFVIIIproduct |
|
Peter Turecek |
|
1 |
|
6/21/2012 6:29:00 PM
|
|
|
| Susceptibility of von Willebrand factor from different mammalian species tocleavage by human recombinant ADAMTS13 |
|
Peter Turecek |
|
1 |
|
6/21/2012 6:23:00 PM
|
|
|
| Establishment of a manufacturing process for recombinant human ADAMTS13retaining high specific activity |
|
Peter Turecek |
|
1 |
|
6/21/2012 6:13:00 PM
|
|
|
| Influence of expression of recombinant human ADAMTS13 in cell lines fromdifferent species on its glycosylation pattern and pharmacokinetics |
|
Peter Turecek |
|
1 |
|
6/21/2012 6:07:00 PM
|
|
|
| 2D-DIGE As a Tool to Analyze Lot-to-Lot Consistency of Complex TherapeuticProducts Such As BAX 855, a PEGylated Recombinant FVIII |
|
Peter Turecek |
|
1 |
|
6/21/2012 5:57:00 PM
|
|
|
| Factor XIII levels in Haemophilia; Treatment Implications |
|
Ole Halfdan Larsen |
|
1 |
|
6/21/2012 2:14:00 PM
|
|
|
| Roman Numerals to Denote Clotting Factors: A Potential Source of Medical Errors |
|
David Page |
|
1 |
|
6/19/2012 2:39:00 PM
|
|
|
| CTP - A CLINICALLY VALIDATED TECHNOLOGY FOR ELONGATING THE HALF LIFE OF COAGULATION FACTORS, ENABLING A PROLONGED HAEMOSTATIC ACTIVITY IN HEMOPHILIC ANIMAL MODEL |
|
Gili Hart |
|
1 |
|
6/17/2012 1:01:00 PM
|
|
|
| One Year Clinical Experience with Mini-Pool Solvent/Detergent-filtered (SD-F)Plasma |
|
El Ekiaby Magdy |
|
1 |
|
5/11/2012 5:54:00 PM
|
|
|
| Real-time Evaluation of Thrombin-mediated Release of Factor VIII Variants from||von Willebrand Factor |
|
Sam Garcia Perez |
|
1 |
|
4/27/2012 1:06:00 PM
|
|
|
| |
|
|
|
|
|
|
